US 12286431
Crystalline forms of a KRas G12C inhibitor
granted A61PA61P35/00
Quick answer
US patent 12286431 (Crystalline forms of a KRas G12C inhibitor) held by Mirati Therapeutics, Inc. expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Mirati Therapeutics, Inc.
- Grant date
- Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 19
- CPC classes
- A61P, A61P35/00